CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
March 20, 2020—DiaSorin Molecular announced it has received emergency use authorization from the FDA for its Simplexa COVID-19 Direct kit. The kit provides a sample-to-answer test for the detection of SARS-CoV-2 directly from nasopharyngeal swab specimens.
“We are excited for the launch of our COVID-19 test and hope to help reduce the current shortage of tests being experienced by hospitals worldwide,” John Gerace, president of DiaSorin Molecular, said in a press release. “This test will better enable clinicians to make appropriate diagnostic decisions by providing rapid and accurate results. We know it will play a critical role in containing the pandemic.”
Pages: 1 2